Literature DB >> 9338724

Urolithiasis associated with the protease inhibitor indinavir.

R G Bruce1, L C Munch, A D Hoven, R S Jerauld, R Greenburg, W H Porter, P W Rutter.   

Abstract

OBJECTIVES: To report the association between the protease inhibitor indinavir and the development of urolithiasis.
METHODS: Case reports of three adult patients infected with the human immunodeficiency virus who developed surgical renal stones while being treated with indinavir are presented.
RESULTS: Of the 3 patients requiring surgical intervention, stone analyses were available in 2. One stone revealed an inner core of an unidentifiable crystal surrounded by calcium oxalate, and another was found to have indinavir components as determined by thin-layer chromatography and gas chromatography-mass spectrometry. Metabolic evaluation of all 3 patients identified significant hypocitraturia as an isolated finding.
CONCLUSIONS: The widely used protease inhibitor indinavir is associated with the development of urolithiasis and may act as a nidus for heterogeneous nucleation leading to the development of mixed urinary stones. Surgical intervention may be necessary in some cases. Underlying metabolic abnormalities may contribute to the increased incidence of stone formation. Urologists and other health care providers should be aware of this association, as combined medical and surgical intervention may be necessary.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9338724     DOI: 10.1016/S0090-4295(97)00399-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  12 in total

Review 1.  Indinavir: a review of its use in the management of HIV infection.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Urological management of indinavir-associated acute renal failure in HIV-positive patients.

Authors:  C Kalaitzis; P Passadakis; S Giannakopoulos; S Panagoutsos; E Mpantis; A Triantafyllidis; S Touloupidis; V Vargemezis
Journal:  Int Urol Nephrol       Date:  2006-12-19       Impact factor: 2.370

3.  Indinavir crystallization and urolithiasis.

Authors:  F Grases; A Costa-Bauzá; R García-González; A Payeras; A Bassa; J J Torres; A Conte
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

4.  Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.

Authors:  Smita A Kshirsagar; Terrence F Blaschke; Lewis B Sheiner; M Krygowski; Edward P Acosta; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-09-27       Impact factor: 2.745

5.  Moderate hyperbilirubinemia improves renal hemodynamics in ANG II-dependent hypertension.

Authors:  Trinity Vera; David E Stec
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-07-28       Impact factor: 3.619

6.  Renal stone composed of ritonavir.

Authors:  Anna M Zhao; Nancy R Angoff
Journal:  BMJ Case Rep       Date:  2019-07-01

7.  Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.

Authors:  A Hsu; G R Granneman; G Cao; L Carothers; A Japour; T El-Shourbagy; S Dennis; J Berg; K Erdman; J M Leonard; E Sun
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 8.  Urologic complications of HIV and AIDS.

Authors:  Chris F Heyns; Adam E Groeneveld; Nelson B Sigarroa
Journal:  Nat Clin Pract Urol       Date:  2009-01

9.  Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients.

Authors:  Christos Kalaitzis; Georgios Dimitriadis; Triantafylos Tsatidis; Rainer Kuntz; Stavros Touloupidis; Georgios Kelidis
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

10.  [Indinavir urolithiasis in HIV-positive patients. Treatment and prophylaxis].

Authors:  C Kalaitzis; S Touloupidis; E Patris; K Lehrich; R M Kuntz
Journal:  Urologe A       Date:  2004-02       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.